These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37961700)

  • 41. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.
    Cacemiro MDC; Cominal JG; Pereira LM; Berzoti-Coelho MG; Berbel GM; Baroni L; Malta T; Tognon R; Nunes NS; Souto EX; de Figueiredo-Pontes LL; Yatsuda AP; de Castro FA
    Med Oncol; 2022 May; 39(5):97. PubMed ID: 35599283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
    Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet function studies in myeloproliferative neoplasms patients with
    Guy A; Helzy K; Mansier O; Bordet JC; Rivière E; Fiore M; James C
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100060. PubMed ID: 36908768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early and late stage MPN patients show distinct gene expression profiles in CD34
    Baumeister J; Maié T; Chatain N; Gan L; Weinbergerova B; de Toledo MAS; Eschweiler J; Maurer A; Mayer J; Kubesova B; Racil Z; Schuppert A; Costa I; Koschmieder S; Brümmendorf TH; Gezer D
    Ann Hematol; 2021 Dec; 100(12):2943-2956. PubMed ID: 34390367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Austrian recommendations for the management of essential thrombocythemia.
    Buxhofer-Ausch V; Heibl S; Sliwa T; Beham-Schmid C; Wolf D; Geissler K; Krauth MT; Krippl P; Petzer A; Wölfler A; Melchardt T; Gisslinger H
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):52-61. PubMed ID: 33215234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are MPNs vascular diseases?
    Finazzi G; De Stefano V; Barbui T
    Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
    Meyer SC; Drexler B; Skoda RC
    Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
    Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
    Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
    Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
    He ZP; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Agarwal MB; Malhotra H; Chakrabarti P; Varma N; Mathews V; Bhattacharyya J; Seth T; Gayathri K; Menon H; Subramanian PG; Sharma A; Bhattacharyya M; Mehta J; Vaid AK; Shah S; Aggarwal S; Gogoi PK; Nair R; Agarwal U; Varma S; Prasad SV; Manipadam MT
    Indian J Med Paediatr Oncol; 2015; 36(1):3-16. PubMed ID: 25810569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombocytosis and Thrombosis: Is There Really a Correlation?
    Galvez C; Stein BL
    Curr Hematol Malig Rep; 2020 Aug; 15(4):261-267. PubMed ID: 32399765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
    Loscocco GG; Guglielmelli P; Vannucchi AM
    Onco Targets Ther; 2020; 13():12367-12382. PubMed ID: 33293830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.